An van Es-Johansson
Direktor/Vorstandsmitglied bei SAVARA INC.
Vermögen: 2 360 $ am 30.04.2024
Aktive Positionen von An van Es-Johansson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SAVARA INC. | Direktor/Vorstandsmitglied | 03.12.2019 | - |
Independent Dir/Board Member | 03.12.2019 | - | |
PLUS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
Independent Dir/Board Member | 01.01.2020 | - | |
LUMOS PHARMA, INC. | Direktor/Vorstandsmitglied | 13.02.2021 | - |
Independent Dir/Board Member | 13.02.2021 | - | |
van Es Consulting AB | Direktor/Vorstandsmitglied | - | - |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Direktor/Vorstandsmitglied | - | - |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Direktor/Vorstandsmitglied | 01.07.2019 | - |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Direktor/Vorstandsmitglied | 01.02.2021 | - |
Karriereverlauf von An van Es-Johansson
Ehemalige bekannte Positionen von An van Es-Johansson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MEDIVIR AB | Direktor/Vorstandsmitglied | 09.05.2019 | 05.05.2022 |
Independent Dir/Board Member | 09.05.2019 | 05.05.2022 | |
ALZECURE PHARMA AB | Direktor/Vorstandsmitglied | 01.09.2018 | 03.03.2020 |
Technik-/Wissenschafts-/F&E-Leiter | 03.03.2020 | 01.03.2021 | |
░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von An van Es-Johansson
Erasmus University Rotterdam | Doctorate Degree |
Statistik
International
Schweden | 7 |
Vereinigte Staaten | 6 |
Niederlande | 3 |
Operativ
Director/Board Member | 11 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 10 |
Health Services | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 8 |
---|---|
BIOINVENT INTERNATIONAL AB | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
ALZECURE PHARMA AB | Health Technology |
MEDIVIR AB | Health Technology |
SAVARA INC. | Health Technology |
PLUS THERAPEUTICS, INC. | Health Technology |
LUMOS PHARMA, INC. | Health Technology |
IRLAB THERAPEUTICS AB | Health Technology |
Private Unternehmen | 4 |
---|---|
van Es Consulting AB | |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
- Börse
- Insiders
- An van Es-Johansson
- Erfahrung